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Summary Amplification and overexpression of the erbB-2 oncogene is an unfavourable prognostic marker in
human breast cancer and occurs in approximately 25% of breast carcinomas. We used erbB-2 antisense
oligonucleotides to inhibit the proliferation of human breast cancer cell lines. erbB-2 antisense oligonucleotides
(20 JLM) inhibited the growth and DNA synthesis of breast cancer cell lines with an amplified erbB-2 gene by
up to 60%. Control complementary sense oligonucleotides did not inhibit cellular proliferation at the same
concentration but showed inhibitory effects at higher concentrations. There was no specific effect of erbB-2
antisense oligonucleotides on breast cancer cell lines that had no amplification of erbB-2. erbB-2 antisense
oligonucleotides reduced erbB-2 protein levels, measured by immunohistochemistry, in a dose-dependent
manner. erbB-2 sense oligonucleotides did not decrease the levels of erbB-2 protein. These data indicate that
erbB-2 antisense oligonucleotides induce a specific inhibition of erbB-2 protein expression and that erbB-2 gene
overexpression is important for the proliferation of the breast cancer cells that have been selected for erbB-2
amplification.
The erbB-2 oncogene (also called neu and HER-2) codes for
a 185 kDa transmembrane growth factor receptor with an
intracellular tyrosine kinase catalytic domain (Schechter et
al., 1985; Coussens et al.. 1985; Yamamoto et al., 1986). The
erbB-2 gene copy number is amplified in many adenocarci-
nomas and, in particular, erbB-2 is amplified or overex-
pressed in approximately 25% of human breast carcinoma
samples (Maguire & Greene, 1989). Overexpression of erbB-2
has not been observed in normal adult human tissues (Press
et al., 1990). Amplification or overexpression of erbB-2 in
malignant breast tumours has been correlated with nodal
metastases, early relapse and shortened survival (Slamon et
al., 1987; Tandon et al.. 1989; Wright et al., 1989; Paik et al..
1990). Moreover, expression of high levels of erbB-2 onco-
gene is sufficient to induce neoplastic transformation of some
cell lines (DiFiore et al., 1987; Hudziak et al.. 1987; Tarak-
hovsky et al., 1990). A role for erbB-2 in the aetiology of
some breast carcinomas was further suggested by transgenic
mouse experiments. in which animals expressing the erbB-2
gene under the control of a steroid-inducible promoter mani-
fested a breast adenocarcinoma phenotype (Muller et al.,
1988; Bouchard et al., 1989).
It has been shown that monoclonal antibodies against the
erbB-2 oncoprotein applied to cells transformed by the rat
neu oncogene cause them to revert to a non-transformed
phenotype (Drebin et al., 1985; van Leeuwen et al., 1990),
and these antibodies diminished the in vivo tumorigenicity of
transplanted murine fibroblasts transformed by neu (Drebin
et al., 1986, 1988). In addition, monoclonal antibodies to the
human erbB-2 protein also inhibited the in vitro growth of
the erbB-2-overexpressing human breast cancer cells SK-Br-3
by 56% (Hudziak et al., 1989). The antiproliferative effects of
the erbB-2 antibodies are related to their ability to down-
regulate the erbB-2 protein. While erbB-2 antibodies which
reduce the levels of erbB-2 exhibit antiproliferative effects,
monovalent F(ab) fragments (Drebin et al., 1986; Kumar et
al., 1991; Sarup et al., 1991) or erbB-2 antibodies which do
not down-regulate erbB-2 (Sarup et al., 1991; Tagliabue et
al., 1991) do not show growth-inhibitory effects.
Antisense oligonucleotides have been used for the specific
study of gene expression. They also represent a new class of
potential pharmacological agents for in vivo antiviral or
antineoplastic therapy (Helene, 1989; Tidd, 1990; Uhlmann &
Peyman, 1990: Carter & Lemoine, 1993). Antisense oligo-
nucleotides have been used to study the in vitro cellular
effects of oncogenes and growth factors in cells from leu-
kaemia (Holt et al., 1988; Wickstrom et al., 1988; Reed et al..
1990; Szcyzylik et al., 1991), lymphoma (McManaway et al.,
1990) and solid cancers (Rosolen et al., 1990; Melani et al.,
1991; Morrison, 1991; Saison-Behmoaras et al., 1991).
We report the effect of erbB-2 antisense oligonucleotides
on cell proliferation and erbB-2 protein expression in breast
cancer cells. The results show that the proliferation of human
breast cancer cells - measured by cell growth and DNA
synthesis - can be inhibited following treatment with anti-
sense oligonucleotides and that this effect is specific for breast
cancer cells which present erbB-2 amplification. In addition,
expression of the erbB-2 oncogene product in breast cancer
cells is reduced in a dose-dependent fashion by erbB-2 anti-
sense, but not sense, oligonucleotides, indicating that overex-
pression of erbB-2 is important for the proliferation of those
cells that have been selected for erbB-2 gene amplification.
Materials and metbods
Oligonucleotides
Oligonucleotides were synthesised on a Milligen/Biosearch
DNA Cyclone by means of phosphoramidite chemistry. The
lyophilised product was dissolved in TE buffer (1O mM Tris
Cl, I mM EDTA, pH 7.4) and stored at - 20°C. We selected
sequences from the 5' end of the erbB-2 gene and performed
a computer search in the GenBank database to obtain in-
formation about other possible sequence matches. For our
experiments we chose a 21-nucleotide sequence directed
against the 5'-translated end of erbB-2 that showed no
sequence matches against the database, and a partially over-
lapping 15-mer that also included the erbB-2 initiation codon
and had imperfect matches to human crystallin and keratin
K7 genes. Their complementary sense sequences were used as
controls. The oligonucleotide sequences are as follows: 1,
15-mer antisense, GGC CGC CAG CTC CAT; 2, 15-mer
sense, ATG GAG CTG CGC GCC; 3, 21-mer antisense,
GCG GCA CAA GGC CGC CAG CTC; 4, 21-mer sense,
GAG CTG GCG GCC TTG TGC CGC. In some experiments,
a 21-mer was synthesised with the same overall oligo-
nucleotides content as 3, but with a random order (nonsense
21-mer).
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Cell lines
The breast cancer cell lines SK-Br-3, BT474, MDA-MB-453,
MDA-MB-361 and MDA-MB-468 were obtained from the
American Tissue Culture Collection (Rockville, MD, USA)
and maintained in Iscove's modified Eagle medium (IMEM)
supplemented with 5% fetal calf serum (FCS) and glutamine
at 37°C in a 5% carbon dioxide incubator. MCF-7 cells are
routinely passaged in our laboratory. SK-Br-3, BT-474,
MDA-MB-453 and MDA-MB-361 cells have 4- to 8-fold
amplification of erbB-2 (Kraus et al., 1987). erbB-2 protein
expression of the cell lines was evaluated by immunostaining
with an erbB-2 monoclonal antibody (no. 94, a gift from
C.R. King, Molecular Oncology, Gaithersburg, MD, USA)
and analysed on a fluorescence-activated cell sorter (FACStar
Plus, Becton Dickinson). SK-Br-3, BT-474, MDA-MB-453
and MDA-MB-361 cells expressed elevated amounts of erbB-
2 protein, while MCF-7 cells showed low levels, and MDA-
MB-468 cells did not express detectable levels of the protein
by FACS (data not shown).
Culture medium andoligonucleotide stability
To ensure that the oligonucleotides added to the cell cultures
lasted for the duration of the assays, we tested the stability of
oligonucleotides in different culture media. Serum-free medium
consisted of IMEM (Biofluids) with the addition of fibronec-
tin 2 mg 1-' (Collaborative Research), transferrin 5mg 1'
(Sigma), 20 mM HEPES (Biofluids), trace elements (Bio-
fluids), glutamine (Biofluids) and 10-7 M insulin (Biofluids).
To assay the stability of oligonucleotides in media over
time, oligonucleotides were added to IMEM containing 5%
FCS or serum-free medium and incubated at 3TC. Samples
of 0.4 ml ofmedium were aliquoted at specified times, phenol
extracted, ethanol precipitated, and run on a 20% polyac-
rylamide gel. Seventy micrograms of a 20-mer oligo-
nucleotide was incubated with 2.8 ml of serum-containing
medium at 37C. Twenty-five micrograms of a 21-mer was
incubated with 2 ml of serum-free medium.
Uptake offluoresceinated oligonucleotides
For oligonucleotide uptake experiments, aminolinker-deriv-
atised oligonucleotides were synthesised on an Applied
Biosystems 381A DNA synthesiser. Oligonucleotides were
incubated with a fluorescein isothiocyanate (FITC) sodium
carbonate/sodium bicarbonate - water - dimethylformamide
(5:8:2) solution overnight in the dark. The reaction mixture
was passed through a Sephadex G50 column to remove
excess FITC, eluting with 20% ethanol in water. The frac-
tions selected showed simultaneous absorption at 260 nm
(DNA) and 500 nm (FITC).
To analyse cellular fluorescence, cells were plated in six-
well plates at a concentration of 106 cells per well and
allowed to attach overnight. Medium was then changed to
serum-free medium containing 50 LM fluorescein-labelled
oligonucleotides, and incubated overnight. After washing the
wells with phosphate-buffered saline (PBS) cells were detach-
ed with PBS-EDTA, and cellular fluorescence was quantitat-
ed using a fluorescence-activated cell sorter (FACStar Plus).
To assess whether the fluorescence assessed by FACS was
intracellular, we used fluorescence microscopy. Cells were
plated in eight-well Lab-Tek chamber slides (Miles Labs,
Naperville, IL, USA) at a concentration of 10,000 cells per
well and allowed to attach overnight. Medium was then
changed to serum-free medium containing 50pM fluorescein-
labelled oligonucleotides, and incubated overnight. The slide
was washed, fixed with 2% formalin and covered with a
coverslip. Samples were visualised by epi-illumination on a
Zeiss Photomicroscope III.
Cellproliferation experiments
For cell growth assays, cells were plated in 24-well plates
(Costar) in IMEM supplemented with 5% FCS to facilitate
attachment to the culture dish. After 24 h, medium was
changed to serum-free defined medium, with or without in-
creasing concentrations of erbB-2 sense or antisense oligo-
nucleotides. After 7 days, cells were detached from the wells
with 5 mM EDTA in PBS and counted in a Coulter counter
(Hialeah, FL, USA).
We also evaluated the effect of oligonucleotides on the
incorporation of [3H]thymidine into cellular DNA. SK-Br-3
cells were incubated for 4 h in a defined serum-free medium containing different concentrations of 15-mer erbB-2 anti-
sense and sense oligonucleotides. The medium was then
replaced with 250gI of 10% FCS-IMEM supplemented with
10;LCi mlj- [3H]thymidine. After 3 h, cells were harvested,
sonicated and treated with 10% trichloroacetic acid (TCA).
TCA precipitates were collected on HA 0.45 pm filters (Milli-
pore) and radioactivity was counted.
erbB-2protein analysis
Immunohistochemical staining and quantitation of erbB-2
protein have been described previously (Bacus et al., 1990).
In brief, exponentially growing SK-Br-3 cells were plated in
four-chamber slides (Nunc, Napperville, IL, USA) at 0.5 x
10' cells per chamber. After 24 h, the medium was replaced
with serum-free medium with or without erbB-2 oligonucleo-
tides. After 6 days, cells were stained with the HER-2/neu
oncogene staining kit (Cell Analysis Systems, Elmhurst, IL,
USA), using a monoclonal antibody against erbB-2 (Ab-2,
Oncogene Science, Manhasset, NY, USA) at a concentration
of I0Ojgml-'. Cells were counterstained with Feulgen DNA
stain (Cell Analysis Systems). The CAS 200 Image Analyzer
(Cell Analysis Systems), with its two solid-state image-sensing
channels specifically matched to the two components of the
stains used (blue stain for DNA and red stain for erbB-2
protein), was used to quantitate average total erbB-2 protein
per cell and the total cellular DNA. Sparsely growing cells
were used for calibrating the cellular erbB-2 protein content.
At least 300 cells were counted for each determination. The
analyser sums the total intensity of protein staining and
divides by the total number of cells counted to determine the
staining index.
Results
Oligonucleotide stability anduptake
We first wanted to be sure that the oligonucleotides used to
treat the cells were stable in culture media and were taken up
by the cells. After exposure to serum-containing medium
oligonucleotides underwent rapid exonucleolytic cleavage. At
2 h, a stepladder pattern of the synthetic DNA was apparent,
and no oligonucleotide was detected in the gel after 10 h. On
the other hand, oligonucleotides were not detectably degrad-
ed in serum-free medium, and the band was unchanged after
up to 7 days of exposure. Therefore, we used serum-free
medium for our experiments. The cell lines used in our study
had equivalent growth in this medium as in medium contain-
ing 5% fetal calf serum.
Since we were going to study breast cancer cell lines which
might incorporate oligonucleotides at different rates, we
evaluated the uptake offluoresceinated oligonucleotides using
a fluorescence-activated cell sorter. The mean cellular fluo-
rescence of the different cell lines was similar after exposure
to 50ylM FITC-labelled oligonucleotide, and did not cor-
relate with the presence of erbB-2 gene amplification or with
the cell size (Table I). We used fluorescence microscopy to
study the pattern of cellular staining that resulted in our
experiments with labelled oligonucleotides. After exposure
cells to FITC-labelled oligonucleotides, the location of the
fluorescent label was predominantly intracellular.
Inhibition ofcellproliferation
The effect of erbB-2 antisense oligonucleotides on breast
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Table I Uptake offluoresceinated oligonucleotide by the different cell
lines used in the study
Cell line Meanfluorescence Median cell size' (pmtn
SK-Br-3 82 30
BT-474 60 28
MDA-453 77 23
MDA-361 72 25
MDA468 65 20
MCF-7 72 32
"Estimated using 10 m beads (Coulter. Hialeah. FL. USA).
including both cell growth and DNA synthesis assays. The
complementary sense oligonucleotides were used as controls
in all experiments. We observed that the addition of erbB-2
antisense oligonucleotides to cell lines that have an amplified
erbB-2 oncogene resulted in a dose-dependent inhibition of
cell growth. Treatment of SK-Br-3 cells for 7 days with
20pM 21-mer erbB-2 antisense oligonucleotide resulted in a
57% cell growth inhibition when compared with untreated
cells or cells treated with sense oligonucleotides. This reduc-
tion in cell number was significant as determined by the
Student's t-test (P = 0.04). Untreated cells or cells treated
with 20pM 21-mer sense oligonucleotide underwent 4.5
doublings, while cells treated with antisense oligonucleotide
underwent two doublings. We also explored whether this
antiproliferative effect was dependent on the dose of the
antisense oligonucleotides, and the results are shown in
Figure la. A dose-response relationship of cell growth
inhibition was observed when increasing concentrations of
21-mer antisense oligonucleotides were added to the cultured
(Figure la). A similar result was observed with 15-mer
antisense oligonucleotides (Figure la). In contrast, the
growth of cells treated with sense strand oligonucleotides at
concentrations of 20gM or less was equivalent to that of
untreated cells. At a concentration of 40pM, however, a 29%
inhibition of growth was observed with the 15-mer sense
strand, and a 15% inhibition of growth was observed with
the 21-mer sense strand.
To be sure that the cell growth inhibition by erbB-2 anti-
sense oligonucleotides was not an idiosynchratic response of
SK-BR-3 cells, we used other cell lines with erbB-2 ampli-
fication to test the antiproliferative effect of erbB-2 antisense
oligonucleotides. Similarly to the results observed in SK-Br-3
cells, 60% growth inhibition was observed in the BT-474 cell
line at an antisense oligonucleotide concentration of 20 jM
(Figure lb). BT-474 cells treated for 7 days with 20pM
erbB-2 antisense oligonucleotides increased cell number by a
factor of 1.1, while cells treated with the same concentration
of sense oligonucleotide underwent a 2.5-fold increase. erbB-2
antisense oligonucleotide concentrations of 100 JM induced a
30% inhibition of growth in the lines MDA-MB-453 and
MDA-MB-361, which also have amplification of erbB-2, but
there was no apparent inhibitory effect on these cell lines by
the sense strand oligonucleotides at 100 IM oligonucleotide
concentrations. Since uptake of oligonucleotide was similar
in all the cell lines tested, differences in cell line sensitivity to
erbB-2 antisense oligonucleotides may be due to variation in
the growth dependance of a particular cell on the erbB-2
oncogene signal.
We used MDA-MB-468 and MCF-7 cell lines, which do
not have erbB-2 amplification, as controls to study the
specificity of the effects of erbB-2 antisense oligonucleotides
on cultured breast cancer cells. MDA-MB-468 cells have
undetectable levels of erbB-2 and overexpress the epidermal
growth factor receptor gene. MCF-7 cells have low levels of
erbB-2, as assessed by flow cytometry. Both cell lines were
shown to have an uptake of FITC-labelled oligonucleotide
similar to the cell lines with erbB-2 amplification (Table I).
We observed no differences in cell growth of MDA-MB-468
cells when antisense and sense erbB-2 oligonucleotide
treatments were compared (Figure lc). Dose-related non-
specific toxicity was seen in this cell line to the degree that
cell growth was inhibited 20% at 100 jM of either sense and
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Fuge 1 Effect of erbB-2 oligonucleotides on the proliferation of
breast cancer ceLls. a, SK-Br-3 cells were grown for 7 days in
serm-free medium with the addition of different concentrations
of 21-mer (0, sense; *, antisense) and 15-mer (0, sense; 0,
antisense), erbB-2 oligonucleotides. b, BT-474 cells were incubat-
ed for 7 days in serum-free medium containing 20 gm erbB-2
21-mer oligonucleotides. c, MDA-MB-468 cells were treated for
12 days with different concentrations of 21-mer (-, sense; 0,
antisense) erbB-2 oligonucleotides. Data are presented as mean+
s.d. of three independent determinations. The number of cells in
each well on the day that oligonucleotides were added to the
cultures is indicated on the vertical axis. Data points that appear
to lack error bars have small standard deviations that are within
the range of the data point.
antisense oligonucleotides. Similarly, no sequence-specific
effects of erbB-2 antisense oligonucleotides were observed in
MCF-7 cells.
To examine whether the antiproliferative effects of erbB-2
antisense oligonucleotides were reflected by changes in cel-
lular DNA synthesis, we assayed short-term incorporation of
[3Hjthymidine into DNA after exposure to 15-mer oligo-
nucleotides. As shown in Figure 2, thymidine incorporation
into DNA was inhibited in SK-Br-3 cells by the erbB-2
antisense oligonucleotides in a dose-dependent manner. The
control sense strand had no effect on DNA synthesis at
concentrations up to 10iM, but caused non-specific inhibi-
tion of thymidine incorporation at 40ILM, which was consis-
tent with the oligonucleotides toxicity threshold for SK-Br-3
cell growth. Differences in [3HJthymidine incorporation were
not due to competition of free thymidine resulting from
oligonucleotides degradation, since the number of thymidine
residues in both the sense and antisense 15-mer erbB-2
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oligonucleotides was the same. As seen in Figure 2, antisense
oligonucleotide concentrations as low as 5tLM were effective
at inhibiting [3Hjthymidine incorporation, while 20iLM was
the lowest concentration at inhibiting cell growth. Since the
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thymidine incorporation experiment was done over a time
course of 4 h and cell number in the growth experiment was
counted after 7 days, these two results cannot be compared
directly. The efficacy of the oligonucleotides in culture may
diminish over 7 days even though we could not demonstrate
appreciable degradation in serum-free medium.
Inhibition oferbB-2protein expression
The effect of erbB-2 antisense oligonucleotides on cellular
erbB-2 protein expression was assessed immunohistochem-
ically and quantitated using an computerised image analysis
system. Breast cancer cells with erbB-2 amplification were
incubated for 6 days with 21-mer erbB-2 oligonucleotides.
erbB-2 staining can be observed in Figure 3. Untreated SK-
Br-3 cells exhibited a clear membrane staining for the erbB-2
protein. The erbB-2 staining index of SK-Br-3 cells treated
0 5 10 15 20 25 30 35 40
Oligonucleotide concentration (pM)
Figwe 2 DNA synthesis of SK-Br-3 cells treated with erbB-2
oligonucleotides (0, sense; 0, antisense). SK-Br-3 cells growing
exponentially in a 24-well plate were incubated for 4h in a
defined serum-free medium containing increasing concentrations
of 15-mer erbB-2 antisense and sense oligonucleotides. The
medium was then replaced with 250 il of 10% FCS-IMEM
supplemented with I01iCiml-' of ['Hjthymidine. After 3 h, cells
were harvested, sonicated and DNA was precipitated with 10%
trichloroacetic acid. Error bars represent the standard deviation
of three paralkl determinations. Data points that appear to lack
error bars have standard deviations that are within the range of
the data point. DPM, dots per minute.
Table II erbB-2 protein levels in SK-Br-3 breast cancer cells treated
with 21-mer erbB-2 oligonucleotides in serum-free medium
Concentration ( lAm) erbB-2 staining indexa (%)
Control 0 0.9 (100)
Antisense 2.5 0.8 (98)
5 0.75 (83)
20 0.6 (66)
50 0.5 (55)
Sense 2.5 1.4 (156)
5 1.28 (142)
20 1.5 (167)
50 1.3 (144)
'Relative to staining of SK-Br-3 cells growing sparsely.
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Fiwe 3 Immunohistochemical appearance of SK-Br-3 cells incubated for 6 days with erbB-2 oligonucleotides. The colour red
indicates staining for the erbB-2 oncoprotein, as described in the Material and methods section. Top left: Control cells not treated
with oligonucleotides. Top right: Cells treated with sense erbB-2 oligonucleotides. Bottom left: Cells treated with nonsense erbB-2
oligonucleotides. Bottom right: Cells treated with antisense erbB-2 oligonucleotides. The last panel shows a marked reduction of
erbB-2 stain.
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with 20gM erbB-2 antisense oligonucleotides was approx-
imately 66% that of untreated cells (Table II). The erbB-2
protein levels were inhibited in a dose-dependent manner by
erbB-2 antisense oligonucleotides, with a 50% reduction
obtained with 50 M. Comparatively, the sense oligonucleo-
tides did not decrease erbB-2 levels at 50 M.
We consistently observed enhanced erbB-2 staining index
in cells treated with sense oligonucleotides. This same effect
was seen when a scrambled-sequence nonsense oligonucklo-
tide was used (Figure 3 and data not shown). We were
unable to explain this non-specific effect, which did not cor-
relate with oligonucleotide concentration. However, the
apparent enhancement of the staining reaction by oligo-
nucleotides suggests that the magnitude of the inhibitory
effect of antisense oligonucleotides may be an underesimate
of the actual effect.
Our experiments provide evidence that erbB-2 overexpression
is important for the in vitro proliferation of human breast
carcinoma cell lines derived from tumours with an amplfied
erbB-2 gene. The decrease in erbB-2 protein levels induced by
erbB-2 antisense oligonucleotides significntly reduced cel-
lular growth and thymidin incorporation into DNA of these
breast cancer cell lines. This antiproliferative effect was
specific, sine control oligonucleotides, which did not reduce
erbB-2 protein levels, had no effect on cellular growth or
DNA synthesis. The specificity of the effect of erbB-2 anti-
sense oligonucleotides was fiuther demonstrated by their lack
of effect on MDA-MB-468 and MCF-7 cels, which do not
express or express low levels of erbB-2.
erbB-2 antisense oligonucleotides did not arrest completely
the growth of the cells overexpressng erbB-2. In our experi-
ments we observed a maximum of 60% inhibiton of growth.
We geerally treated our cultures once with oligonuclotides
and measured growth at 7 days. Since intracellular degrada-
tion of oligonucleotides occurs, a daily treatment may have
achieved a greater degree of cell growth inhibition. Further-
more, the cell lines used in these experiments contained other
genetic alterations in addition to erbB-2 amplification, which
also may drive cell growth independent oferbB-2. For exam-
ple, SK-Br-3 cells express c-fins and CSF-I and have an
amplification of the c-myc gene (Horiguchi et al., 1988).
MDA-MB-453 and MDA-MB-361 ells overexpress erbB-3
(Kraus et al., 1989; Plowman et al., 1990). BT474 and
MDA-MB-361 cells express oestrogen and progesterone
receptors and manifest a growth response to oestradiol treat-
ment in vitro and also when grown in nude nide (R- Col-
omer & E.P. Gelmann, unpublished data).
A third possible explanation for our results is the existence
ofcell line heterogeneity. Preliminary evidence from 20 clonal
derivatives of SK-Br-3 cells shows that the antiproliferative
effects of erbB-2 antisense oligonucleotides are retained by
less than 50% of the clones, and that this is not related to
loss of expression of erbB-2 protein. A recent report has
suggested that a subline of the lymphoma cls DHL-4
develops resistance to an antisense oligonucleotide by the
emergence of intracellular degradation that is absent in the
parental line (Ryte et al., 1993). Tberefore there may be
cellular heterogeneity ring sensitivity to oligonucle-
tides, and resistance to these agents may be a problem in
future experiments. Nevertheless, our finding that erbB-2
antisense oligonucleotides inhibit the growth of cells over-
expressing erbB-2 by 50-60% is consistet with a similar
inhibition of proliferation observed in SK-Br-3 cells with
erbB-2 antibodies (Hudziak et al., 1989).
We have shown that erbB-2 antisense oligonucleotides
induce a dose-related decrease in erbB-2 protein levels
measured by immunohistochemistry in SK-Br-3 cells. A
20 FM concentration of erbB-2 antisense oligonucleotide
induced a 35% decrease in erbB-2 protein staining Cells
treated with sense erbB-2 oligonucleotides, in contrast, did
not decrease erbB-2 levels and rather showed an increase in
erbB-2 protein staining. The specificity of the effect of
antisense oligonucleotides was further substantiated by the
fact that we observed no reduction in erbB-2 staining by
erbB-2 sense oligonucleotides, even at concentrations at
which these compounds had non-specific antiproliferative
effects. The erbB-2 staining increase induced by erbB-2 sense
oligonucleotides does not seem to be specific for the sense
sequence that we used, since it did not correlate with the
concentration of oligonucleotide and, furthermore, other
unrelated oligonucleotides induced a smilar small increase in
erbB-2 staining (data not shown). erbB-2 antisense oligonu-
cleotides decreased the levels of erbB-2 protein in the cell
membrane without a concurrent increase in intracellular
stain, which is consistent with a decreased erbB-2 protein
synthesis. This contrasts with the down-regulating effect of
the erbB-2 ligand gp3O on cells overexpressng erbB-2. gp3O
decreases membrane-associated erbB-2, but partly at the
expense of increased intracellular accumulation of erbB-2
protein (Bacus et al., 1992).
By inhibiting the expression of erbB-2 protein with anti-
sense oligonucleotides we have shown that breast cancer cells
with erbB-2 amplifction are subject to specific growth
inhibition. Our results support the hypothesis that erbB-2
oncogene amplification confers a growth advantage on cells
(DiFiore et al., 1987; Hudziak et al., 1987). Other procedures
that decrease erbB-2 levels interfere with cellular prolifera-
tion. The selective pressure provided by very high erbB-2
receptor levels can be reversed using monoclonal antibodies
to erbB-2 (Drebin et al., 1988; Hudziak et al., 1989). In
addition, we have reported that elevated concentrations of
gp3O are growth inlhibtory in cells with elevated expression
of erbB-2 (Lupu et al., 1990). Clinically, erbB-2 is over-
expressed in 25% of human primary breast carcinomas, and
it is correlated with an adverse prognosis. The experimental
data strongly suggest that the erbB-2 oncogene and its pro-
duct can be potential therapeutic targets in a signiiant
fraction ofbreast carcinomas. Therapeutic strategies aimed at
the erbB-2 gene may have a relatively high therapeutic index.
We make this speculation based on the fact that two cancer
cell lines without erbB-2 overexpression showed no growth
effects after erbB-2 antisense oligonucleotides treatment and,
similarly erbB-2 antibodies and gp30 had no antiproliferative
effects on cells without overexpression (Hudziak et al., 1989;
Lupa et al., 1990). This theoretical approach is further sup-
ported by the observations that there is homogeneous over-
expression of erbB-2 among the cancer cells in breast
tumours that overexpress the oncogene (Iglehart et al., 1990),
while the surrounding mammary tissue is essentially void of
erbB-2 overexpression, as are other normal tissues through-
out the body (Press et al., 1990). Antisnse oligonucleotides
chemical analogues synthesisd to confer relative serum and
cellular nuclease resistance represent a new class of com-
pounds with potential appUlcation for gene-specific thera-
peutic intervention (Tidd, 1990). Experiments with these
agents n vivo will help define the spectrum of applications
for oligonucleotides and their derivatives.
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